1. Airway-derived emphysema-specific alveolar type II cells exhibit impaired regenerative potential in COPD.
- Author
-
Hu Y, Hu Q, Ansari M, Riemondy K, Pineda R, Sembrat J, Leme AS, Ngo K, Morgenthaler O, Ha K, Gao B, Janssen WJ, Basil MC, Kliment CR, Morrisey E, Lehmann M, Evans CM, Schiller HB, and Königshoff M
- Subjects
- Animals, Humans, Mice, Male, Disease Models, Animal, Pulmonary Surfactant-Associated Protein C metabolism, Female, Organoids, Uteroglobin metabolism, Uteroglobin genetics, Pulmonary Alveoli cytology, Pulmonary Alveoli pathology, Stem Cells cytology, Stem Cells metabolism, Middle Aged, Pulmonary Disease, Chronic Obstructive physiopathology, Pulmonary Disease, Chronic Obstructive metabolism, Alveolar Epithelial Cells metabolism, Regeneration, Pulmonary Emphysema physiopathology, Pulmonary Emphysema metabolism
- Abstract
Emphysema, the progressive destruction of gas exchange surfaces in the lungs, is a hallmark of COPD that is presently incurable. This therapeutic gap is largely due to a poor understanding of potential drivers of impaired tissue regeneration, such as abnormal lung epithelial progenitor cells, including alveolar type II (ATII) and airway club cells. We discovered an emphysema-specific subpopulation of ATII cells located in enlarged distal alveolar sacs, termed asATII cells. Single-cell RNA sequencing and in situ localisation revealed that asATII cells co-express the alveolar marker surfactant protein C and the club cell marker secretaglobin-3A2 (SCGB3A2). A similar ATII subpopulation derived from club cells was also identified in mouse COPD models using lineage labelling. Human and mouse ATII subpopulations formed 80-90% fewer alveolar organoids than healthy controls, indicating reduced progenitor function. Targeting asATII cells or their progenitor club cells could reveal novel COPD treatment strategies., Competing Interests: Conflict of interest: C.M. Evans reports grants from Cystic Fibrosis Foundation, Department of Defense, and Enterprise Therapeutics, outside the submitted work, and royalties from Eleven P15 consulting. C.R. Kliment serves on an advisory board of Verona Pharmaceuticals. The remaining authors have no conflicts of interest., (Copyright ©The authors 2024.)
- Published
- 2024
- Full Text
- View/download PDF